Iambic Therapeutics, a clinical-stage biotechnology company, has partnered with Lambda to utilize an NVIDIA HGX B200 cluster to advance its AI-driven drug discovery platform, specifically enhancing its Enchant model for molecular property prediction. Announced on June 26, 2025, this collaboration aims to accelerate the development of novel medicines by improving prediction accuracy for clinical and preclinical endpoints.
Iambic selects Lambda’s NVIDIA HGX B200 cluster to train Enchant v2.
Enchant v2 predicts biological, pharmacokinetic, and safety properties with high accuracy.
Reduces drug development timelines by up to 50% compared to traditional methods.
Outperforms in vitro testing for in vivo drug clearance predictions.
Lambda’s 1-Click Clusters enable seamless scaling for Iambic’s AI models.
Iambic’s $100M Series B (2023) supports clinical asset advancement.
Enchant v2, Iambic’s multimodal transformer model, predicts dozens of molecular properties critical for drug development, including pharmacokinetics, safety, and efficacy. “Enchant v2 provides accurate predictions where data is most sparse,” said Matt Welborn, Iambic’s VP of Machine Learning. Trained on 10x more data than its predecessor, Enchant v2 achieves a 30% improvement in prediction accuracy, per Iambic’s benchmarks, enabling multi-parameter optimization and faster clinical trial design. Notably, it outperforms traditional in vitro testing for in vivo drug clearance, aligning with FDA’s push for in silico methods.
Lambda’s NVIDIA HGX B200 cluster provides the computational power needed to scale Enchant’s training, supporting complex AI workloads. “The scale and stability of the Lambda cluster, accelerated by NVIDIA, helped enable us to train NeuralPLexer3,” Welborn noted previously, a sentiment echoed for Enchant v2. Lambda’s 1-Click Clusters allow Iambic to spin up high-performance compute in seconds, reducing training time by 40% compared to less scalable systems. This partnership builds on Iambic’s prior collaboration with NVIDIA, which powered IAM1363, a HER2 inhibitor now in Phase 1 trials.
Iambic, founded in 2020 and backed by $100M from investors like NVIDIA and Ascenta Capital, operates in the $1.1T AI market and $150B drug discovery sector. Its platform, including Enchant and NeuralPLexer, cuts drug development timelines from six years to under two, as seen with IAM1363. The NVIDIA HGX B200 cluster’s deployment aligns with the 25% annual growth in AI-driven biotech, competing with firms like Recursion. Posts on X highlight Iambic’s Lambda partnership as a game-changer, though some note high compute costs as a barrier for smaller firms.
Iambic’s collaboration with Lambda and NVIDIA positions it to redefine drug discovery, delivering faster, more effective medicines to address unmet patient needs.
The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence.
Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at Iambic.ai
Lambda was founded in 2012 by AI engineers with published research at the top machine learning conferences in the world. Our goal is to become the #1 AI compute platform serving developers across the entire AI development lifecycle. We enable AI engineers to easily, securely and affordably build, test and deploy AI products at scale. Our product portfolio spans from on-prem GPU hardware to hosted GPUs in the cloud. Lambda’s mission is to create a world where access to computation is as effortless and ubiquitous as electricity.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.